

**Supplemental Table 5. Intracranial efficacy in patients with at least one measurable CNS lesion, excluding those who stopped brain radiotherapy <12 weeks before starting lorlatinib**

	≥1 prior second-generation ALK TKI (EXP3B–5)	1 prior second-generation ALK TKI (EXP3B)	≥2 prior ALK TKIs (EXP4–5)
<i>N</i>	49	7	42
ORR, <i>n</i> (%)	28 (57.1)	5 (71.4)	23 (54.8)
95% CI	42.2–71.2	29.0–96.3	38.7–70.2
Best overall IC response, <i>n</i> (%)			
Complete response	12 (24.5)	2 (28.6)	10 (23.8)
Partial response	16 (32.7)	3 (42.9)	13 (31.0)
Stable disease / no response	13 (26.5)	0	13 (31.0)
Progressive disease	5 (10.2)	1 (14.3)	4 (9.5)
Indeterminate	3 (6.1)	1 (14.3)	2 (4.8)
Duration of IC objective response, <sup>a</sup> months			
<i>N</i>	28	5	23
Median	12.4	4.2	12.4
95% CI	5.8–37.1	4.1–37.1	6.0–NE

ALK, anaplastic lymphoma kinase; CI, confidence interval; CNS, central nervous system; EXP, expansion cohort; IC, intracranial; NE, not estimable; ORR, objective response rate; TKI, tyrosine kinase inhibitor.

<sup>a</sup> Kaplan–Meier estimates; CIs were derived using the Brookmeyer Crowley method